State Street Reports A 7.6% Passive Holding In Rare-Disease Drugmaker Ultragenyx
The ownership report comes while Ultragenyx and Mereo discuss a regulatory path for setrusumab in children with osteogenesis imperfecta.
State Street reported a 7.6% passive holding in Ultragenyx Pharmaceutical, which develops and sells treatments for serious rare and ultra-rare genetic diseases, in an SEC ownership disclosure filed Tuesday. The position covered 7,538,078 common shares as of September 30, 2026.
Ownership Without A Control Campaign
State Street and the other reporting investor certified that their holdings arose from routine business activity, rather than an effort to alter or influence Ultragenyx's control. The report describes ownership at the September measurement date, rather than a purchase made Tuesday.
SSGA Funds Management separately reported 5,318,630 shares, representing 5.4% of the common-stock class. Those figures are separate reporting-person totals and should not be added together.
State Street shared voting authority over 7,245,178 shares; SSGA Funds Management shared that authority over 5,303,530 shares. Neither reported voting authority it could exercise alone.
Setrusumab's Pediatric Regulatory Question
Ultragenyx and partner Mereo BioPharma are discussing with regulators what evidence would be needed for a submission covering setrusumab in children with osteogenesis imperfecta, and whether the treatment has a path forward.
The partners reported results from the late-stage Orbit and Cosmic studies in December 2025. At the ASBMR Annual Meeting in October, they presented additional analyses focused on patients who had experienced at least 3 fractures during the preceding 2 years. Both studies showed benefits in fractures, bone mineral density and other measures in those analyses.
Denise Scots-Knight, chief executive of Mereo BioPharma, said the findings supported setrusumab's potential, especially for pediatric patients with more frequent fractures.
Four Products Beyond The Pipeline
Ultragenyx's marketed treatments include Crysvita for X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii for MPS VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia. Partner Regeneron markets Evkeeza in the U.S.
The company's development portfolio includes biologics, small molecules, gene therapies and nucleic acid candidates, mostly licensed from academic institutions or other drug companies. It sells through its own international commercial teams and uses third-party distributors in smaller markets.
Ultragenyx had a market capitalization of $1.7 billion in Tuesday trading, as of 9:46 a.m. ET.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: ULTRAGENYX PHARMACEUTICAL INC (RARE) — SEC EDGAR
- Mereo BioPharma Reports Third Quarter 2026 Financial — globenewswire.com
